Larvol Delta - AltruBio-presented-its-novel-PSGL1-agonist-antibody-program-at-FOCIS-and-presented-its-phase-2a-Psoriatic-Arthritis-study-results-for-lead-molecule-Neihulizumab-at-ACR

neihulizumab (AbGn-168H) - AbGenomics

https://www.prweb.com/releases/altrubio_presented_its_novel_psgl_1_agonist_antibody_program_at_focis_and_presented_its_phase_2a_psoriatic_arthritis_study_results_for_lead_molecule_neihulizumab_at_acr/prweb17561987.htm

Nov 27, 2020

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next